Journal Information
Vol. 41. Issue 8.
Pages 430-433 (August 2005)
Share
Share
Download PDF
More article options
Vol. 41. Issue 8.
Pages 430-433 (August 2005)
Original Articles
Full text access
T2N1M0 Non-Small Cell Lung Cancer: Surgery and Prognostic Factors
Visits
6897
J. Padilla
Corresponding author
jpadilla@comv.es

Correspondence: Dr. J. Padilla. Servicio de Cirugía Torácica. Hospital Universitario La Fe. Avda. de Campanar, 21. 46009 Valencia. España
, V. Calvo, J.C. Peñalver, C. Jordá, J. Escrivá, J. Cerón, A. García Zarza, J. Pastor, E. Blasco
Servicio de Cirugía Torácica, Hospital Universitario La Fe, Valencia, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Objective

TO determine the prognostic factors for the survival in a group of patients operated on for a non-small cell lung cancer classified as T2N1M0.

Patients and methods

TWO hundred sixteen patients treated exclusively with surgery were studied. Kaplan-Meier survival and Cox multivariable regression analyses were used.

Results

The overall survival rate was 39.8% at 5 years and 29.9% at 10 years. Sex, age, presence or absence of symptoms, type of resection, and number and location of affected lymph nodes had no effect on survival. Tumor size (P = .04) and histologic type (P = .03) did significantly affect prognosis. Both variables entered into the Cox multivariable regression model.

Conclusions

Patients operated on for non-small cell lung cancer classified as T2N1M0 have an overall probability of 5-year survival of approximately 40%. However, the prognosis for this group of patients is heterogeneous: in our study it was affected by the histologic type (45.5% for squamous cell and 25% for non-squamous cell cancers) and tumor size (53% for tumors with a diameter of ≤3 cm, 45% for tumors between 3.1 and 5 cm, and 29% for a tumor diameter >5 cm).

Key Words:
Carcinoma bronchogenic
Stage IIb
T2N1M0
Surgery
Prognosis
Objetivo

Determinar los factores pronósticos de supervi-vencia de un grupo de pacientes operados de un carcinoma broncogénico no anaplásico de células pequeñas y clasifica-dos como T2N1M0.

Pacientes y métodos

Se estudió a 216 pacientes tratados exclusivamente con cirugía. La supervivencia se analizó con el método de Kaplan-Meier y se utilizó el modelo de Cox para el análisis multivariante.

Resultados

La supervivencia global fue del 39,8% a los 5 años y del 29,9% a los 10 años. El sexo, la edad, la presen-cia o ausencia de síntomas, la amplitud de la exéresis, el nú-mero de ganglios afectados y su localización no influyeron en la supervivencia. El tamaño tumoral (p = 0,04) y la estir-pe histológica (p = 0,03) sí condicionaron significativamente el pronóstico. Ambas variables entraron en regresión cuan-do se utilizó el análisis multivariante.

Conclusiones

Los pacientes operados de un carcinoma broncogénico no anaplásico de células pequeñas clasificado como T2N1M0 tienen una probabilidad de supervivencia global a los 5 años en torno al 40%. Sin embargo, no es un grupo de pacientes con un pronóstico homogéneo, ya que en nuestro estudio estuvo condicionado por la estirpe histológica (un 45,5% para los epidermoides y un 25% para los no epidermoides) y el tamaño tumoral (un 53% en los tumores con un diámetro ≤ 3 cm, un 45% entre 3,1-5 cm y un 29% en > 5 cm).

Palabras clave:
Carcinoma broncogénico
Estadio IIb
T2N1M0
Cirugía
Factores pronósticos
Full text is only aviable in PDF
REFERENCES
[1]
Grupo de Trabajo de la SEPAR.
Normativa actualizada (1998) sobre diagnóstico y estadificación del carcinoma broncogénico.
Arch Bronconeumol, 34 (1998), pp. 437-452
[2]
N Martini, M Burt, M Bains, P McCormack, V Rusch, R Ginsberg.
Survival after resection of stage II non-small cell lung cancer.
Ann Thorac Surg, 54 (1992), pp. 460-466
[3]
CF Mountain.
Revision in the international staging system for lung cancer.
Chest, 111 (1997), pp. 1710-1717
[4]
K Inoue, M Sato, S Fujimura, A Sakurada, S Takahashi, K Usuda, et al.
Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993.
J Thorac Cardiovasc Surg, 116 (1998), pp. 407-411
[5]
T Naruke, R Tsuchiya, H Kondo, H Asamura.
Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience.
Ann Thorac Surg, 71 (2001), pp. 1759-1764
[6]
V Calvo Medina, J Padilla Alarcón, F París Romeu, E Blasco Armengod, J Pastor Guillem, A García Zarza.
Supervivencia posquirúrgica en el estadio II del carcinoma broncogénico no anaplásico de células pequeñas.
Arch Bronconeumol, 37 (2001), pp. 19-26
[7]
E van Velzen, RJ Snijder, A Brutel de la Rivière, HJ Elbers, JM van den Bosch.
Lymph node type as a prognostic factor for survival in T2N1M0 non-small cell lung carcinoma.
Ann Thorac Surg, 63 (1997), pp. 1436-1440
[8]
T Naruke, K Suemasu, S Ishikawa.
Lymph node mapping and curability at various levels of metastasis in resected lung cancer.
J Thorac Cardiovasc Surg, 76 (1978), pp. 832-839
[9]
T Yano, H Yokoyama, T Inoue, H Asoh, K Tayama, Y Ichinose.
Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma.
J Thorac Cardiovasc Surg, 107 (1994), pp. 1398-1402
[10]
M Riquet, D Manac'h, F le Pimpec-Barthes, A Dujon, A Chehab.
Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung.
Ann Thorac Surg, 67 (1999), pp. 1572-1576
[11]
A Marra, L Hillejan, G Zaboura, T Fujimoto, D Greschuchna, G Stamatis.
Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis.
J Thorac Cardiovasc Surg, 125 (2003), pp. 543-553
[12]
T Osaki, A Nagashima, T Yoshimatsu, Y Tashima, K Yasumoto.
Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer.
Lung Cancer, 43 (2004), pp. 151-157
[13]
Sayar A, Turna A, Kilicgun A, Solak O, Urer N, Gurses A. Prognostic significance of surgical-pathologic multiple-station N1 disease in non-small cell carcinoma of the lung. Eur J Cardiothorac Surg. 200;25:434-8.
[14]
S Watanabe, G Ladas, P Goldstraw.
Inter-observer variability in systematic nodal dissection: a comparison of European and Japanese nodal designation.
Ann Thorac Surg, 73 (2002), pp. 245-248
[15]
H Asamura, K Suzuki, H Kondo, R Tsuchiya.
Where is the boundary between N1 and N2 stations in lung cancer?.
Ann Thorac Surg, 70 (2000), pp. 1839-1842
[16]
PORT Meta-analysis Trialists Group.
Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials.
Lancet, 352 (1998), pp. 257-263
[17]
Non-small Cell Lung Cancer Collaborative Group.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials.
BMJ, 311 (1995), pp. 899-909
[18]
The International Adjuvant Lung Cancer Trial Collaborative Group.
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
N Engl J Med, 350 (2004), pp. 351-360
[19]
KMW Pister, RJ Ginsberg, DJ Giroux, JB Putnam, MG Kriss, DH Johnson, et al.
Induction chemotherapy before surgery for early-stage lung cancer: a novel approach.
J Thorac Cardiovasc Surg, 119 (2000), pp. 423-439
[20]
A Depierre, B Milleron, D Moro-Sibilot, S Chevret, E Quoix, B Lebeau, et al.
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0) II, and IIIa non-small cell lung cancer.
J Clin Oncol, 20 (2002), pp. 247-253
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?